CSL Ltd: Targeting sustainable, profitable growth
About the author:
- Author name:
- By Dr Derek Jellinek
- Job title:
- Senior Analyst
- Date posted:
- 17 October 2023, 7:00 AM
- Sectors Covered:
- The inaugural Capital Markets Day offered the opportunity to better understand the strategic direction across core franchises (ie Behring; Seqirus; Vifor), vet the growing R&D portfolio and glimpse at information and digital initiatives.
- Management expressed confidence in CSL’s resilience (ie no material impact from GLP-1s) and competitive advantages in scaled operations, reiterating FY24 guidance and calling for annual double-digit earnings growth over the medium-term.
- This growth is underpinned via a leading position in large, growing markets, and focus on improving plasma yields, lowering costs, a disciplined approach to digitalisation, and new drug launches to improve Behring GMs (3-5 years to pre-COVID levels), with ROIC improving over time.
- We make no changes to our forecasts or (login to view) PT. Add.
Find out more
Download full research note
If you would like more information, please contact your adviser or nearest Morgans office.
Request a call
Find local branch
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.
Print this page